PSC
SRPT icon

Portman Square Capital’s Sarepta Therapeutics SRPT Stock Holding History

Portman Square Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-548,300
Closed -$52.9M – 438
2023
Q4 		$52.9M Buy
+548,300
New +$52.6M 1.21% 15

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Portman Square Capital's SRPT Position: Q1 2024 in Review

Portman Square Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 97,927 shares — an estimated $9.44M sold.

Portman Square Capital first reported a position in SRPT in Q3 2023 and held it in 2 quarters. The position peaked at $9.44M in Q4 2023. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Portman Square Capital reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Portman Square Capital sold 97,927 Sarepta Therapeutics shares in Q1 2024, an estimated $9.44M.
  • Portman Square Capital first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 2 quarters.
  • Portman Square Capital's Sarepta Therapeutics position peaked at $9.44M in Q4 2023.
  • 415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Portman Square Capital's 13F filing for Q1 2024, filed 15 Apr 2024.